{"nctId":"NCT01609010","briefTitle":"A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma","startDateStruct":{"date":"2002-10"},"conditions":["Lymphoma"],"count":313,"armGroups":[{"label":"Rituximab Monotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: rituximab"]},{"label":"Rituximab, Interferon","type":"EXPERIMENTAL","interventionNames":["Drug: rituximab","Drug: interferon-a-2a"]}],"interventions":[{"name":"rituximab","otherNames":["MabThera","Rituxan"]},{"name":"interferon-a-2a","otherNames":["Roferon-A"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients \\>18 years of age\n* CD20+ low-grade (indolent) lymphoma of follicular and marginal zone type, small lymphocytic lymphoma without a B-CLL phenotype, or indolent lymphoma not otherwise specified\n* Stage II (with bulky disease), III, or IV lymphoma\n* No previous chemotherapy or a maximum of 6 months chlorambucil or cyclophosphamide\n* Indication for treatment: symptomatic enlarged lymph nodes, spleen or other lymphoma manifestations, progression \\>6 months of lymphadenopathy or splenomegaly, anemia or thrombocytopenia or decreased hemoglobin or platelets due to lymphoma, general symptoms (weight loss, night sweats or fever)\n* WHO performance status 0-2\n\nExclusion Criteria:\n\n* Prior treatment with rituximab or an interferon\n* B-CLL, mantle cell lymphoma, lymphoplasmacytic lymphoma (Waldenstroem's disease), or central nervous system lymphoma\n* Indolent lymphoma transformed into aggressive lymphoma\n* Indolent lymphoma with bulky tumor requiring urgent therapy\n* Prior malignancies, except non-melanoma skin tumors, in situ cervical cancer, or curative surgery \\>5 years ago\n* Positive for HIV infection\n* Uncontrolled asthma or allergy requiring corticosteroids","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Failure - Percentage of Participants With an Event","description":"Treatment failure was defined as an event of any of the following: progressive disease while receiving study treatment, death due to any cause, or the initiation of another type of treatment due to stable disease, progressive disease or relapse, or intolerance to study treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]}]},{"type":"PRIMARY","title":"Treatment Failure - Time to Event","description":"The median time, in months, between randomization and treatment failure event determined using Kaplan-Meier estimates.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":null},{"groupId":"OG001","value":"28.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Complete Response (CR), Unconfirmed CR (CRu), or Partial Response (PR)","description":"CR was defined as the complete disappearance of all previously detectable disease signs; the absence of palpable lymph nodes greater than (\\>) 1 centimeter (cm) or nodes \\>1.5 cm observed in computerized axial tomography (CAT) scan; and negative bone marrow pathology, if initially positive. CRu was defined as CR, except that bone marrow results were indeterminate. PR was defined as a decrease of greater than or equal to (≥) 50 percent (%) compared with the BL value in the sum of the products of the two largest perpendicular diameters in all measurable and evaluable lesions; and a ≥50% reduction of the size from BL if hepato-splenomegaly was present.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving CR or CRu","description":"CR was defined as the complete disappearance of all previously detectable disease signs; the absence of palpable lymph nodes \\>1 cm or nodes \\>1.5 cm observed in CATscan; and negative bone marrow pathology, if initially positive. CRu was defined as CR, except that bone marrow results were indeterminate.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response - Percentage of Participants With an Event","description":"Response duration was defined as the period between the date for first observation of CR, CRu or PR and the date of progressive disease (PD), censored observation or death of any cause. Response duration was also assessed for response defined as CR only. Response duration was calculated among responders (CR+CRu+PR) with cutoffs for follow-up applied.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"The median time, in months, from the date of the first observation of CR, CRu, or PR and the date of progressive disease (PD), censored observation, or death due to any cause. PD was defined as an increase of \\>50% compared to BL in the sum of the product of the two largest perpendicular parameters of measurable lymphoma, or the occurrence of new lesions. One month=30.4 days. Response duration was calculated amongst responders (CR+CRu+PR) with cutoffs for follow-up applied.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"30.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":null},{"groupId":"OG001","value":"50.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Progression - Percentage of Participants With an Event","description":"A disease progression event was defined as tumor progression or death due to any cause (or a censored observation).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Disease Progression","description":"The median time, in months, from randomization to disease progression event assessed using Kaplan-Meier estimates. One month=30.4 days","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"32.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - Percentage of Participants With an Event","description":"An overall survival event was defined as death due to any cause.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"The median time, in months, from randomization to OS event assessed using Kaplan-Meier estimates. One month=30.4 days","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":156},"commonTop":["General disorders and ASC","Gastrointestinal disorders","Musculoskeletal and connective tissue disorders","Nervous system disorders","Infections and infestations"]}}}